Dementia: The neurochemical basis of putative transmitter orientated therapy

Pharmacology and Therapeutics

Volumn 52, Issue 3, 1991, Pages 423-443

  Court, J A ^a   Perry, E K ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; 5 ISOPROPOXY 4 METHYL BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; ACETYLCHOLINESTERASE; ARECOLINE; BETHANECHOL; CATECHOLAMINE; CHOLINE ACETYLTRANSFERASE; CORTICOTROPIN RELEASING FACTOR; CYCLOSERINE; ENZYME INHIBITOR; MILACEMIDE; MUSCARINIC RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; OXOTREMORINE; PHYSOSTIGMINE; RIVASTIGMINE; SELEGILINE; SEROTONIN; SOMATOSTATIN; SURONACRINE; TACRINE; VELNACRINE MALEATE;

ADRENERGIC SYSTEM; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; CHOLINERGIC SYSTEM; COGNITION; DEMENTIA; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEMORY; MOUSE; NEUROTRANSMISSION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVIEW; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; CHOLINESTERASE INHIBITORS; DEMENTIA; HUMAN; MONOAMINE OXIDASE INHIBITORS; NEUROCHEMISTRY; NEUROTRANSMITTERS; PARASYMPATHOLYTICS; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC;

EID: 0026386753     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(91)90035-K     Document Type: Article

References (180)

1. Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase
2. Peptides and Parkinson's disease
3. Tetrahydro-9-aminoacridine (THA) interacts with the phencyclidine (PCP) receptor site
4. Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quanternary structure
5. The role of the metabotropic receptor in synaptic plasticity
6. Hill coefficients and the logistic equation
7. 3 receptor antagonist, on cognition in rodent and primates
8. Cigarette smoking and Parkinson's disease
9. Inositol trisphosphate, a novel second messenger in cellular signal transduction
10. Selective changes in sensitivity to cholinergic agonists and receptor changes elicited by continous physostigmine infusion
11. Regulation of brain nicotinic receptors by chronic agonist infusion
12. The molecular basis of muscarinic receptor diversity
13. Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's disease
14. Two distinct kinetic phases of desensitization of acetylcholine receptors of clonal rat PC12 cells
15. Spin-labelling studies of the interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA), a proposed drug for the treatment of Alzheimer's disease, with erythrocyte membranes
16. Dementia associated with cortical Lewy bodies: proposed clinical diagnostic criteria
17. Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia
18. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicenter trial
19. Non-NMDA receptor mediated neuronal injury in Alzheimer's disease
20. Possible mechanisms limiting N-methyl-D-aspartate receptor overactivation and the therapeutic efficay of N-methyl-D-aspartate antagonists
21. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry
22. Decreased levels of protein kinase C in Alzheimer brain
23. Dissociation of the apparent relationship between nicotine tolerance and up-regulation of nicotinic receptors
24. N-methyl-D-aspartate receptors and Alzheimer's disease
25. 3H]MK-801 to brain membranes, but not via the stimulation of high-affinity nicotinic receptors
26. The role of the nucleus basalis of Meynert and dementia: review and reconsideration
27. VIP-sensitive adenylate cyclase, guanylate cyclase, muscarinic receptors, choline acetyl-transferase,and acetylcholinesterase, in brain tissue afflicted by Alzheimer's disease/senile dementia of the Alzheimer type
28. Cholinergic mechanisms in schizophrenia, mania and depression
29. s is deficient in Huntington's disease
30. 1-dopamine receptor abnormality in frontal cortex points to a functional alteration of cortical cell membranes in Alzheimer's disease
31. Heterogeneity of nicotine actions in the rat cerebellum: and in vivo electrophysiologic study
32. Pharmacological and functional diversity of neuronal nicotin acetylcholine receptors
33. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat
34. 3H]forskolin binding sites in Alzheimer's disease: a quantitative autoradiographic study
35. Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease—an autoradiographic study of the hippocampus
36. Positive and negative effects of tacrine (tetrahydroamino acridine) and methoxytacrine on the metabolism of acetylcholine in brain cortical prisms incubated under ‘resting’ conditions
37. + current
38. Cholinergic grafts, memory and ageing
39. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions
40. Tacrine in Alzheimer's disease
41. 2 muscarinic receptor
42. Pharmacological and clinical-pharmacological properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor
43. Functions of the locus coeruleus noradrenergic system: a neurobiological and behavioural snthesis
44. Peptides in the neocortex in Alzheimer's disease and ageing
45. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal
46. + channel by tacrine: interactions with muscarinic and adenosine receptors
47. Selective effector coupling of muscarinic acetylcholine receptor subtypes
48. Tetra-hydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease: results of a Canadian double-blind, crossover, multicenter study
49. Plasticity of hippocampal circuitry in Alzheimer's disease
50. The cholinergic receptor system of the human brain: neurochemical and pharmacological aspects in aging and Alzheimer's
51. Muscarinic agonists for senile dementia: past experience and future trends
52. Excitatory amino acids and Alzheimer's disease
53. Milacemide, a glycine prodrug, enhances performances of learning tasks in normal and anmestic rodents
54. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity
55. Amyloid deposition as the central event in the aetiology of Alzheimer's disease
56. Metabolic and functional studies on post-mortem human brain
57. The effect of long-term physostigmine administration in Alzheimer's disease
58. Distribution of a kainate/AMPA receptor mRNA in normal and Alzheimer brain
59. α) mRNA in hippocampal and cortical neurons
60. Terminal coma affects messenger RNA detection in post mortem human temporal cortex
61. The role of neuronal energy in the neurotoxicity of excitatory amino acids
62. The prevalence of dementia in Europe: a collaborative study of 1980–1990 findings
63. Autoradiographic imaging of [3H]phorbol-12,13-dibutyrate binding to protein kinase C in Alzheimer's disease
64. The mechanism of protein kinase C activation
65. Serotonergic involvement in learning and memory
66. 125I]ggalanin binding sites despite loss of cholinergic neurons to the hippocampus in Alzheimer's disease
67. Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly control patients
68. 3H]dopamine release in rat striatum
69. Role of NMDA receptors in memory
70. Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopamine neurons in the male rat
71. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial
72. Glycine potentiates the NMDA response in cultured mouse brain neurons
73. Nicotinic cholinergic receptors in Alzheimer's Disease
74. Distribution of nerve growth factor receptor immunoreactivity in the human hippocampus
75. β-Amyloid protein increases the vulnerability of cultured neurons to excitotoxic damage
76. The role of nerve growth factor in the CNS
77. Alterations in neuropeptides in aging and disease: pathophysiology and potential for clinical intervention
78. Neocortical concentration of neuropeptides in senile dementia of the Alzheimer and Lewy body type comparisons with Parkinson's disease and severity correlations
79. Prospect of transplantation in human neurodegenerative disease
80. Neurotransmitter regulation of neuronal outgrowth, plasticity and survival
81. Effect of nicotine and tacrine on acetylcholine release from rat cerebral cortical slices
82. Both α- and β-subunits contribute to the agonist sensitivity of neuronal and nicotinic acetylcholine receptors
83. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers
84. Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine and alpha-bungarotoxin
85. Selectivity of excitotoxic mechanisms in Alzheimer's disease
86. Neuropeptides in Alzheimer's disease
87. Acetylcholine induces burst firing in thalamic reticular neurons by activating a potassium conductance
88. Age-associated memory impairment: a role for catecholamines
89. Serotonin, memory and the aging brain
90. Robustness of proteins in Alzheimer's disease: an immunoblot study
91. Excitatory amino acid neurotoxicity and neurodegenerative disease
92. The revenge of the kainate receptor
93. Alterations in neocortical expression of nicotinic acetylcholine receptor mRNAs following unilateral lesions of the rat nucleus basalis magnocellularis
94. Clonidine treatment of Alzheimer's disease
95. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease
96. The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system
97. D-Cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performances of learning tasks in rats
98. Selegiline in the treatment of mild to moderate Alzheimer-type dementia
99. Anomalous molecular form of actylcholinesterase in cerebrospinal fluid in histologically diagnosed Alzheimer's disease
100. Intravenous nicotine in Alzheimer's disease: a pilot study
101. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with neurochemical and behavioural changes
102. Nicotinic receptor deficits in Alzheimer's disease—a possible diagnostic marker
103. Heterogenous cholinergic nicotinic receptors in the CNS
104. Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains
105. 11C-nicotine in brain of Alzheimer patients as visualized by position emission tomography
106. Magnesium gates glutamate-activated channels in mouse central neurons
107. Reduced cAMP-signal transduction in postmortem hippocampus of demented old people
108. 9-Amino-1,2,3,4-tetrahydroaminoacridine (THA) is a potent blocker of cardiac potassium channels
109. Influence of tetrahydro-9-aminoacridine on excitatory amino acid release
110. The cholinergic hypothesis—ten years on
111. Cortical neurotransmitter chemistry in Alzheimer's disease
112. Alzheimer's disease and acetylcholine
113. Current advances in research in Alzheimer's disease
114. Nerve growth factor and the basal forebrain cholinergic system: a link in the aetiopathology of neurodegenerative dementias?
115. Hypothesis linking plasticity, vulnerability and nerve growth factor to basal forebrain cholinergic neurons
116. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
117. Interaction of 9-amino-1,2,3,4- tetrahydroamino-acridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro
118. 3H-nicotine) receptor binding in human brain: characterization and involvement in cholinergic neuropathology
119. Regional distribution of muscarinic and nicotinic cholinergic receptor binding activities in the human brain
120. Evidence of a monoaminergic: cholinergic imbalance related to visual hallucinations in Lewy body dementia
121. Cholinergic and dopaminergic activities in senile dementia of Lewy body type
122. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types
123. Converging archicortical cholinergic activities in aging and Alzheimer's disease
124. Senile dementia of Lewy body type
125. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia
126. 3H]MK801 binding in post mortem human cortex
127. 3H]MK-801 binding in Alzheimer's disease
128. Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease
129. Formation of β-amyloid protein deposits in the brains of transgenic mice
130. Self regulation of membrane receptors
131. Stereo selective nicotine-induced release of dopamine from striatal synaptosomes: concentration dependence and repetitive stimulation
132. Action of nicotine on dopamine pathways and implications for Parkinson's disease
133. 3H](−)-nicotine to rat brain membranes and its inhibition by analogs of nicotine
134. THA increases action potential duration of central histamine neurons in vitro
135. Is senile dementia of the Alzheimer type associated with hippocampal plasticity?
136. Can fetal neural transplants restore function in monkeys with lesion-induced behavioural deficits?
137. Cholinergic treatments for Alzheimer's disease
138. Epidemiology of clinically diagnosed Alzheimer's disease
139. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980–1990 prevalence findings
140. Ann. Neurol.
141. 3H]acetylcholine release from mouse cerebral cortical synaptosomes
142. Evidence for functional activity of up-regulated nicotine binding sites in rat striatal synaptosomes
143. The effects of nicotine on attention, information processing and short-term memory in patients with dementia of Alzheimer type
144. Memory following cholinergic (NBM) and noradrenergic (DNAB) lesions made singly or in combination: potentiation of disruption by scopolamine
145. Treatment strategies for senile dementia: antagonist β-carbolines
146. Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification
147. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells
148. Cholinesterase inhibitor therapy for Alzheimer dementia: what do animal models tell us?
149. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics
150. Blockade of N-methyl-D-aspartate receptors may protect against ischaemic damage in the brain
151. Guanine nucleotide modulation of muscarinic cholinergic receptor binding in postmortem human brain—a preliminary study in Alzheimer's disease
152. Neurochemical and behavioral effects of muscarinic acetylcholine receptor agonists
153. Long-term administration of oral physostigmine in Alzheimer's disease
154. Excitatory actions of tetrahydro-9-aminoacridine (THA) on hippocampal pyramidal neurons
155. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer's-diseased brains
156. Oral tetrahydro-aminoacridine in long term treatment of senile dementia
157. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease
158. The changing scene of neurotrophic factors
159. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
160. Negative effects of tacrine (tetrahydroaminoacridine) and methoxytacine on the metabolism of acetylcholine in brain slices incubated under conditions stimulating neurotransmitter release
161. Relation between nicotine intake and Alzheimer's disease
162. A, muscarinic and β-adrenoceptor and neuron degeneration in cingulate cortex in Alzheimer's disease
163. Distribution of alpha-2, alpha-3, alpha-4 and beta-2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat
164. D-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes
165. 2 muscarinic receptor subtypes
166. Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia
167. The effects of D-cycloserine, a glycine agonist, in a model of the cognitive deficits associated with ageing and dementia
168. D-Cycloserin antagonizes scopolamine induced memory impairment and improves memory in the elderly
169. Reductions in acetylcholine and nicotine binding in several degenerative diseases
170. Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's disease
171. Stability of adenylate cyclase coupling to somatostatin and corticotrophin-releasing-factor receptors in frozen post-mortem human cerebral cortex
172. Expression of nicotine acetylcholine receptor subtypes in brain and retina
173. The expression, localization and functional significance of β-nerve growth factor in the central nervous system
174. Deposits of amyloid β protein in the central nervous system of transgenic mice
175. Alpha-bungarotoxin binds to low-affinity nicotine binding sites in rat brain
176. The paradox of nicotine acetylcholine receptor upregulation by nicotine
177. Parameters of cholinergic neurotransmission in the thalamus in Parkinson's disease and Alzheimer's disease
178. 3H]inositol 1,4,5-triphosphate binding in Alzheimer's disease
179. THA potentiates quinolinates NMDA receptor mediated toxicity
180. Neurochemical correlates of major depression in primary dementia